ProfileGDS5678 / 1451356_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 89% 91% 91% 90% 90% 90% 90% 87% 90% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1525290
GSM967853U87-EV human glioblastoma xenograft - Control 27.2484690
GSM967854U87-EV human glioblastoma xenograft - Control 37.2779790
GSM967855U87-EV human glioblastoma xenograft - Control 47.2600189
GSM967856U87-EV human glioblastoma xenograft - Control 57.4639591
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1404991
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9803290
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2522490
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2047490
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2848290
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6490387
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2994590
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4828591
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3378291